These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

762 related articles for article (PubMed ID: 36529238)

  • 21. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.
    Tao S; Liang S; Zeng T; Yin D
    Front Immunol; 2022; 13():1043667. PubMed ID: 36685594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors.
    Abenavoli L; Montori M; Svegliati Baroni G; Argenziano ME; Giorgi F; Scarlata GGM; Ponziani F; Scarpellini E
    Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629716
    [No Abstract]   [Full Text] [Related]  

  • 23. Resistance to immune checkpoint inhibitors and the tumor microenvironment.
    Kawashima S; Togashi Y
    Exp Dermatol; 2023 Mar; 32(3):240-249. PubMed ID: 36437644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting YAP1 to improve the efficacy of immune checkpoint inhibitors in liver cancer: mechanism and strategy.
    Gao Y; Gong Y; Lu J; Hao H; Shi X
    Front Immunol; 2024; 15():1377722. PubMed ID: 38550587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
    Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.
    Rizzo A; Ricci AD; Gadaleta-Caldarola G; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1245-1251. PubMed ID: 34431725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
    Shen KY; Zhu Y; Xie SZ; Qin LX
    J Hematol Oncol; 2024 Apr; 17(1):25. PubMed ID: 38679698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.
    Lee YH; Tai D; Yip C; Choo SP; Chew V
    Front Immunol; 2020; 11():568759. PubMed ID: 33117354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
    Guardascione M; Toffoli G
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies.
    Atkins MB; Ascierto PA; Feltquate D; Gulley JL; Johnson DB; Khushalani NI; Sosman J; Yap TA; Kluger H; Sullivan RJ; Tawbi H
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma.
    Lee BM; Seong J
    World J Gastroenterol; 2021 Mar; 27(10):919-927. PubMed ID: 33776363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiation therapy in the era of immune treatment for hepatocellular carcinoma.
    Chen L; Zhang R; Lin Z; Tan Q; Huang Z; Liang B
    Front Immunol; 2023; 14():1100079. PubMed ID: 36742293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
    Wong KM; King GG; Harris WP
    Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
    Ding Z; Dong Z; Chen Z; Hong J; Yan L; Li H; Yao S; Yan Y; Yang Y; Yang C; Li T
    Front Immunol; 2021; 12():733530. PubMed ID: 34659220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
    Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
    JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.
    Koh B; Tan DJH; Lim WH; Wong JSL; Ng CH; Chan KE; Wang M; Yong WP; Dan YY; Wang LZ; Tan N; Muthiah M; Kow A; Syn NL; Huang DQ; Yau T
    Oncoimmunology; 2023; 12(1):2214478. PubMed ID: 37284696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy.
    Akce M; El-Rayes BF; Wajapeyee N
    Oncogene; 2023 Mar; 42(14):1051-1057. PubMed ID: 36854723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment.
    Han R; Li J; Hony J; Xiao Z; Wang J; Yao M; Liang S; Lu L
    Front Immunol; 2023; 14():1052657. PubMed ID: 37006233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma.
    Zhu Y; Qin LX
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):420-429. PubMed ID: 35977874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?
    Werner W; Kuzminskaya M; Lurje I; Tacke F; Hammerich L
    Semin Liver Dis; 2024 May; 44(2):159-179. PubMed ID: 38806159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.